{"url":"https://whatshealthyandwhy.com/quercetin/cardiovascular-health-and-blood-pressure","path":"/quercetin/cardiovascular-health-and-blood-pressure","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/quercetin/cardiovascular-health-and-blood-pressure.json","markdown":"https://whatshealthyandwhy.com/quercetin/cardiovascular-health-and-blood-pressure.md"},"topic":{"slug":"quercetin","name":"Quercetin","url":"https://whatshealthyandwhy.com/quercetin"},"slug":"cardiovascular-health-and-blood-pressure","order":2,"title":"Cardiovascular Health and Blood Pressure","question":"Does quercetin lower blood pressure?","answer":"Quercetin supplements of 500 mg or more a day likely lower blood pressure slightly, about 3 mmHg systolic, mainly in people with hypertension.","description":"How quercetin's antioxidant and vasodilatory mechanisms lower blood pressure, protect LDL cholesterol, and support endothelial function in cardiovascular health","confidence":3,"confidenceNote":"Two meta-analyses of RCTs (7 and 10 trials; 587 and 841 people) agree, but trials are short, small and highly variable.","evidenceSummary":{"rctCount":1,"observationalCount":0,"metaAnalysisCount":2,"totalParticipants":"840+","replicated":true,"newestStudyYear":2023},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Supplements & Vitamins","subcategorySlug":"supplements","url":"https://whatshealthyandwhy.com/explore/good-for-you/supplements"},"actions":["Eat onions, capers, apples with skin, berries and kale; food alone rarely reaches the 500 mg a day used in trials [1].","If supplementing, trials used 500–1,000 mg a day with meals; doses under 500 mg did not significantly lower pressure [1].","Choose a phytosome or dihydrate form, which absorbs better than plain quercetin powder, and take it with a fat-containing meal."],"cautions":["It is not a replacement for blood pressure medication; the effect is only about 3 mmHg, so keep diet, exercise and prescribed treatment [1][2].","In 88 heart-attack survivors already on medication, 500 mg a day for 8 weeks did not significantly change blood pressure or inflammation markers [3].","Doses above 1,000 mg a day for long periods raise theoretical kidney concerns from animal data; human trials have not shown harm."],"simpleText":"Quercetin is a flavonoid pigment concentrated in onions, capers, apples, and dark berries, and it is one of the best-studied plant compounds for cardiovascular health. Two meta-analyses of randomized controlled trials confirm that quercetin supplementation produces consistent, modest reductions in both systolic and diastolic blood pressure, with larger effects in people who already have elevated readings [1][2]. It works partly by relaxing blood vessel walls and partly by protecting LDL cholesterol from the oxidative damage that initiates plaque formation [4]. While it is not a replacement for blood pressure medication, the evidence supports quercetin as a meaningful dietary support for heart health alongside a healthy diet and exercise.","mediumText":"How Quercetin Affects the Cardiovascular System\n\nQuercetin influences the cardiovascular system through several overlapping mechanisms.\n\nEndothelial function and nitric oxide. The endothelium — the thin cellular lining of blood vessels — regulates vascular tone by releasing nitric oxide (NO), which signals smooth muscle to relax and vessels to dilate. Quercetin activates endothelial nitric oxide synthase (eNOS), increasing NO production and promoting vasodilation. It also inhibits the phosphodiesterase enzymes that break down cyclic GMP, the intracellular messenger that keeps smooth muscle relaxed. The net result is lower peripheral vascular resistance and reduced blood pressure [4].\n\nACE inhibition. Angiotensin-converting enzyme (ACE) converts angiotensin I to the vasoconstricting peptide angiotensin II, a central driver of hypertension. Quercetin has mild ACE-inhibitory activity, providing a mechanism similar in direction — though far weaker in magnitude — to pharmaceutical ACE inhibitors [5].\n\nLDL oxidation and plaque prevention. Atherosclerosis begins when LDL cholesterol is oxidized by reactive oxygen species in the arterial wall, triggering an inflammatory cascade. Quercetin's strong antioxidant activity — particularly its ability to chelate metal ions that catalyze oxidation and to scavenge free radicals — reduces LDL oxidation. In cell and animal studies, quercetin consistently reduces markers of oxidative LDL modification, which is considered an early-stage driver of plaque formation [4][5].\n\nAnti-inflammatory vascular protection. NF-κB is a transcription factor that drives the expression of pro-inflammatory cytokines involved in vascular damage, foam cell formation, and endothelial dysfunction. Quercetin inhibits NF-κB activation, reducing the production of TNF-α, IL-1β, and IL-6 in vascular tissue. This anti-inflammatory action complements its antioxidant effects and may partly explain its blood pressure-lowering properties, since chronic vascular inflammation contributes to arterial stiffness [4].\n\nBlood Pressure: What the Evidence Shows\n\nThe blood pressure data for quercetin is among the most consistent in the flavonoid literature. Clinical effects are modest but real.\n\nA 2016 meta-analysis (Serban et al.) pooled 7 randomized controlled trials with 587 participants and found that quercetin supplementation significantly reduced both systolic blood pressure (WMD −3.04 mmHg, 95% CI −5.75 to −0.33) and diastolic blood pressure (WMD −2.63 mmHg, 95% CI −4.25 to −1.01) [1]. Subgroup analysis found effects were larger in trials using doses above 500 mg/day and in participants with metabolic syndrome or pre-existing hypertension. Doses below 500 mg/day showed non-significant trends.\n\nA 2022 meta-analysis (Popiolek-Kalisz and Fornal) expanded the evidence base to 10 trials with 841 participants. Across the mixed population, quercetin significantly lowered systolic blood pressure (MD −2.38 mmHg, 95% CI −3.80 to −0.96); the systolic reduction was also significant in the normotensive subgroup (MD −1.82 mmHg, 95% CI −2.43 to −1.20), and diastolic pressure fell significantly in the (pre)hypertensive subgroup (MD −3.14 mmHg, 95% CI −4.44 to −1.84) [2].\n\nThese numbers — roughly 3 mmHg systolic reduction — may seem small, but population-level analyses suggest that sustained reductions of 2–3 mmHg across the population could reduce stroke incidence by 8% and coronary heart disease by 5%.\n\nPost-Heart Attack Evidence\n\nA double-blind, placebo-controlled RCT published in Phytotherapy Research enrolled 88 patients who had survived a myocardial infarction. Participants received either 500 mg/day quercetin or placebo for 8 weeks [3]. The quercetin group showed significant increases in total antioxidant capacity (TAC) compared to placebo — a meaningful finding, since oxidative stress in post-MI patients accelerates further cardiovascular damage. Effects on blood pressure and inflammatory markers (IL-6, CRP) were not statistically significant in this trial, possibly because the 8-week window was too short to see those changes in a post-MI population already receiving standard medications.\n\nDosage and Bioavailability\n\nTypical doses used in cardiovascular trials range from 500–1000 mg/day of quercetin, often divided into two doses. Quercetin's bioavailability from standard supplements is moderate — it absorbs better when taken with food (fat enhances absorption) and when formulated as quercetin phytosome (complexed with phosphatidylcholine) or quercetin dihydrate. Encapsulated forms show higher plasma concentrations than powders in comparative studies.\n\nNatural food sources contain much smaller amounts: a large onion provides roughly 30–50 mg, a cup of capers around 170 mg, an apple about 10–15 mg. Getting 500 mg/day from food alone is not realistic for most diets, which is why supplementation is used in cardiovascular studies.\n\nQuercetin is generally well tolerated. At doses below 1000 mg/day, no significant adverse effects have been reported in clinical trials. At very high doses (>1g/day) for extended periods, there are theoretical concerns about nephrotoxicity based on animal data, though human trials have not demonstrated this risk.\n\nPractical Tips\n\n- Effective dose: 500–1000 mg/day, taken with meals for better absorption\n- Timing: Split into two doses if taking 1000 mg/day\n- Formulation: Quercetin phytosome or quercetin dihydrate tend to absorb better than plain quercetin aglycone powder\n- Food sources to include alongside supplementation: raw onions, capers, apples with skin, dark berries, kale, and dill are the richest dietary sources\n- Pairs well with: vitamin C (enhances antioxidant recycling) and bromelain (may improve absorption, though evidence is mixed); combined products are commonly available\n\nSee our Quercetin — Inflammation, Allergies, and Longevity page for quercetin's other primary uses: anti-inflammatory effects in rheumatoid arthritis, mast cell stabilization for allergies, and its role as a senolytic agent to clear aging cells.","deepText":"Evidence Review\n\nBlood Pressure — Serban et al. (2016)\n\nSerban MC et al. published a systematic review and meta-analysis in the Journal of the American Heart Association (PMID 27405810) pooling seven randomized controlled trials that enrolled 587 participants across different populations including healthy volunteers, metabolic syndrome patients, and type 2 diabetic subjects [1]. Trials ranged from 4 to 10 weeks in duration and used quercetin doses from 150 to 1000 mg/day.\n\nPooled results: significant reductions in both systolic BP (WMD −3.04 mmHg, 95% CI −5.75 to −0.33; p = 0.028) and diastolic BP (WMD −2.63 mmHg, 95% CI −4.25 to −1.01; p = 0.001). Heterogeneity was high (I² = 85% for SBP), reflecting diverse populations and doses.\n\nKey subgroup findings:\n- Doses ≥500 mg/day: significant SBP reduction (WMD −4.45 mmHg); doses <500 mg/day: non-significant\n- Patients with metabolic syndrome: more pronounced BP reduction vs. healthy subjects\n- No significant association between trial duration and effect size\n\nLimitations: High between-study heterogeneity limits meta-analytic precision. Most trials were small (15–93 participants), and few assessed dietary quercetin intake at baseline. Publication bias assessment via funnel plot was inconclusive given the small number of trials.\n\nUpdated Meta-Analysis — Popiolek-Kalisz and Fornal (2022)\n\nPopiolek-Kalisz J and Fornal E updated the evidence base in Current Problems in Cardiology (PMID 35948195) incorporating trials published through 2022, for a total of 10 studies and 841 participants [2]. They specifically examined subgroups by hypertension status, comparing (pre)hypertensive and normotensive adults.\n\nIn the mixed population, quercetin significantly decreased systolic BP (MD −2.38 mmHg, 95% CI −3.80 to −0.96; P = 0.01). The systolic reduction was also significant in the normotensive subgroup (MD −1.82 mmHg, 95% CI −2.43 to −1.20; P < 0.0001), and diastolic BP fell significantly in the (pre)hypertensive subgroup (MD −3.14 mmHg, 95% CI −4.44 to −1.84; P < 0.00001).\n\nThe authors concluded that quercetin supplementation decreases blood pressure in both normotensive and (pre)hypertensive adults.\n\nLimitations: Moderate to high heterogeneity persists across trials. There remains significant variation in quercetin formulation, dose timing, and co-supplements across trials. The majority of evidence still comes from relatively short-duration trials (≤12 weeks).\n\nPost-MI Antioxidant RCT — Dehghani et al. (2021)\n\nDehghani F et al. conducted a double-blind, placebo-controlled trial (PMID 33216421) in Phytotherapy Research enrolling 88 post-myocardial infarction patients at Iran University of Medical Sciences, randomized to 500 mg/day quercetin or placebo for 8 weeks [3]. Primary outcomes included inflammatory markers (CRP, IL-6) and quality of life.\n\nThe key finding was a significant increase in total antioxidant capacity (TAC) in the quercetin group versus placebo (p < 0.05). The insecurity dimension of quality-of-life (measured by the MacNew Heart Disease Health-Related Quality of Life questionnaire) also improved significantly in the quercetin group.\n\nIL-6, CRP, and blood pressure did not reach statistical significance. The authors attribute this partly to the anti-inflammatory and antihypertensive medications most post-MI patients were already receiving — a pharmacological ceiling effect that reduces the observable contribution of a dietary supplement.\n\nLimitations: 8-week duration may be insufficient for inflammatory and blood pressure endpoints in medicated post-MI patients. The study was conducted in a single center with an Iranian population; generalizability to other groups requires further research.\n\nMechanisms Review — Mirsafaei et al. (2020)\n\nMirsafaei L et al. published a narrative review in Plant Foods and Human Nutrition (PMID 32588290) synthesizing evidence on quercetin's molecular targets in cardiovascular disease, with emphasis on mechanisms relevant to clinical outcomes [4]. The authors — cardiovascular specialists from Iran and Croatia — assessed preclinical and clinical data together.\n\nThe review identifies five overlapping cardiovascular mechanisms: (1) antioxidant scavenging of ROS that oxidize LDL cholesterol; (2) eNOS activation leading to increased vascular NO production and vasodilation; (3) ACE inhibition reducing angiotensin II-mediated vasoconstriction; (4) NF-κB inhibition reducing vascular inflammation; and (5) platelet aggregation inhibition that may reduce thrombotic risk. The authors flag the bioavailability problem as the primary barrier to translating strong preclinical results to clinical trials: oral quercetin is extensively metabolized in the gut and liver, and tissue concentrations in humans may be lower than those used in cell and animal experiments.\n\nCardiovascular Review — Zhang et al. (2023)\n\nZhang W et al. published a comprehensive review in Frontiers in Cardiovascular Medicine (PMID 38054093) examining quercetin's therapeutic evidence across hypertension, atherosclerosis, heart failure, and arrhythmia [5]. The review, drawing on both animal models and human clinical data, concludes that evidence for blood pressure reduction and endothelial protection is the strongest, supported by multiple meta-analyses, while evidence for effects on advanced atherosclerosis, heart failure, and arrhythmia remains largely preclinical.\n\nThe authors highlight quercetin's effect on arterial stiffness — measured by pulse wave velocity in some trials — as a potentially important mechanism beyond simple blood pressure reduction, since arterial stiffness is an independent cardiovascular risk factor. They call for trials using pulse wave velocity and flow-mediated dilation as co-primary endpoints alongside BP.\n\nOverall Evidence Assessment …","deepTruncated":true,"references":[{"id":"1","title":"Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Serban MC, Sahebkar A, Zanchetti A, Mikhailidis DP, Howard G, Antal D, Andrica F, Ahmed A, Aronow WS, Muntner P, Lip GYH, Graham I, Wong N, Rysz J, Banach M","year":2016,"journal":"Journal of the American Heart Association","pmid":"27405810","url":"https://pubmed.ncbi.nlm.nih.gov/27405810/"},{"id":"2","title":"The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis","authors":"Popiolek-Kalisz J, Fornal E","year":2022,"journal":"Current Problems in Cardiology","pmid":"35948195","url":"https://pubmed.ncbi.nlm.nih.gov/35948195/"},{"id":"3","title":"Effects of quercetin supplementation on inflammatory factors and quality of life in post-myocardial infarction patients: A double blind, placebo-controlled, randomized clinical trial","authors":"Dehghani F, Sezavar Seyedi Jandaghi SH, Janani L, Sarebanhassanabadi M, Emamat H, Vafa M","year":2021,"journal":"Phytotherapy Research","pmid":"33216421","url":"https://pubmed.ncbi.nlm.nih.gov/33216421/"},{"id":"4","title":"Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment","authors":"Mirsafaei L, Reiner Z, Shafabakhsh R, Asemi Z","year":2020,"journal":"Plant Foods and Human Nutrition","pmid":"32588290","url":"https://pubmed.ncbi.nlm.nih.gov/32588290/"},{"id":"5","title":"Research progress of quercetin in cardiovascular disease","authors":"Zhang W, Zheng Y, Yan F, Dong M, Ren Y","year":2023,"journal":"Frontiers in Cardiovascular Medicine","pmid":"38054093","url":"https://pubmed.ncbi.nlm.nih.gov/38054093/"}],"wordCount":1842,"source":{"path":"src/content/topics/quercetin/cardiovascular-health-and-blood-pressure.md"},"citeAs":"“Does quercetin lower blood pressure?.” What's Healthy and Why. https://whatshealthyandwhy.com/quercetin/cardiovascular-health-and-blood-pressure","notice":"General information backed by peer-reviewed research, not medical advice."}